Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
12.35
+0.09 (0.69%)
At close: Feb 6, 2026, 4:00 PM EST
12.36
+0.01 (0.12%)
After-hours: Feb 6, 2026, 4:04 PM EST
Company Description
Daxor Corporation engages in medical instrumentation and biotechnology operations.
It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Daxor Corporation
| Country | United States |
| Founded | 1970 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Michael Feldschuh |
Contact Details
Address: 109 Meco Lane Oak Ridge, Tennessee 37830 United States | |
| Phone | 865-425-0555 |
| Website | daxor.com |
Stock Details
| Ticker Symbol | DXR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000027367 |
| CUSIP Number | 239467103 |
| ISIN Number | US2394671034 |
| Employer ID | 13-2682108 |
Key Executives
| Name | Position |
|---|---|
| Michael Richard Feldschuh | Chairman, President and Chief Executive Officer |
| Robert J. Michel C.P.A., M.B.A. | Chief Financial Officer, Chief Compliance Officer and Corporate Secretary |
| Jonathan Adam Feldschuh | Chief Scientific Officer and Director |
| Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. | Chief Medical Officer |
| Linda Cooper | Vice President of Development and Operations |
| Kathryn A. Kornafel | Senior Vice President of Marketing and Commercial Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 26, 2026 | 8-K | Current Report |
| Jan 26, 2026 | 424B4 | Prospectus |
| Jan 23, 2026 | 424B3 | Prospectus |
| Jan 23, 2026 | 8-K | Current Report |
| Jan 22, 2026 | 424B3 | Prospectus |
| Jan 20, 2026 | EFFECT | Notice of Effectiveness |
| Dec 29, 2025 | N-2/A | Filing |
| Dec 29, 2025 | N-CEN/A | Filing |
| Dec 29, 2025 | N-CSR/A | Filing |
| Nov 13, 2025 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |